

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 November 2024 (07.11.2024)



(10) International Publication Number
WO 2024/228134 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/24* (2006.01)
A61P 1/04 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2024/054244

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
02 May 2024 (02.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/463,651 03 May 2023 (03.05.2023) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventors: **VETTER, Marion**; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). **TERRY, Natalie A.**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **ROONEY, Terence**; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). **HANS MOORE, Meredith**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **XU, Yan**; 1400 McKean Road, Spring
House, Pennsylvania 19477 (US). **YEAGER, Barry Todd**;
1400 McKean Road, Spring House, Pennsylvania 19477
(US).

(74) Agent: **LANE, David A.** et al.; One Johnson & Johnson
Plaza, Johnson & Johnson, New Brunswick, New Jersey
08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHOD OF TREATING ULCERATIVE COLITIS WITH A COMBINATION OF ANTIBODIES TO IL-23 AND TNF ALPHA

(57) Abstract: A method of treating ulcerative colitis (UC) by administering a combination of an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab), and a TNF- α inhibitor, such as an anti-TNF- α antibody (e.g., golimumab).

WO 2024/228134 A1